• English

上海凡默谷信息技術有限公司

上海凡默谷信息技術有限公司

上海市

021-50263208
客服微信:ipharmogo

周一至周五 9:00~19:00

解決方案
  • 首頁
  • 關于我們
    • 公司簡介
    • 典型用戶
    • 合作伙伴
  • 新聞資訊
    • 培訓通知
    • 公司動態
  • 產品中心
    • GastroPlus
    • ADMET Predictor
    • DDDPlus
    • 其他產品
  • 培訓中心
    • 視頻匯總
    • 技術視頻
    • 凡默谷技術文章
    • 使用FAQ
    • 歷年文獻匯總
  • 在線申請
  • 聯系我們
  • 首頁
  • 關于我們
    • 全部
    • 公司簡介
    • 典型用戶
    • 合作伙伴
  • 新聞資訊
    • 全部
    • 培訓通知
    • 公司動態
  • 產品中心
    • 全部
    • GastroPlus
    • ADMET Predictor
    • DDDPlus
    • 其他產品
  • 培訓中心
    • 全部
    • 視頻匯總
    • 技術視頻
    • 凡默谷技術文章
    • 使用FAQ
    • 歷年文獻匯總
  • 在線申請
  • 聯系我們
GastroPlus在IVIVC, IVIVR, BE考察的應用文章(2012—2020)
  1. 您現在所在位置:
  2. 網站首頁
  3. GastroPlus系列文章匯總

GastroPlus在IVIVC, IVIVR, BE考察的應用文章(2012—2020)

2020-10-17 18:17:49

導  讀


凡默谷技術部精取了2012-2020年10月GastroPlus在IVIVC, IVIVR, BE考察的應用文章58篇。

其中編號1-12的文章是2019年8月-2020年10月新增文章。

希望對您的業務或專業學習有所幫助。內容如下:


1.   具有生物預測性的體外方法:研討會總結報告

In Vitro Biopredictive Methods: A Workshop Summary Report.
Pepin XJ, Dressman J, Parrott N, Delvadia P, Mitra A, Zhang X, Kolhatkar V, Seo P, Taylor LS, Sj?gren E, Butler JM, Kostewicz ES, Tannergren C, Koziolek M, Kesisoglou F, Dallmann A, Zhao Y, Suarez-Sharp S. J Pharm Sci. September 2020.IF= 3.616

2.  使用生理藥代動力學吸收模型建立奧司他韋在成人和兒童人群中的生物等效性溶出安全空間

Using a Physiologically Based Pharmacokinetic Absorption Model to Establish Dissolution Bioequivalence Safe Space for Oseltamivir in Adult and Pediatric Populations
Lei Miao, Youssef M. Mousa, Liang Zhao, Kimberly Raines, Paul Seo, Fang Wu.AAPS J. volume 22, Article number: 107 (2020). IF= 3.737

3.  通過體外溶出曲線相似性支持藥品的質量評估:內容,如何應用,何時應用—研討會總結報告

In Vitro Dissolution Profiles Similarity Assessment in Support of Drug Product Quality: What, How, When—Workshop Summary Report.
Suarez-Sharp S, Abend A, Hoffelder T, Leblond D, Delvadia PR, Kovacs E, Diaz DA.The AAPS Journal (2020) 22:74. IF= 3.737

4.  用于支持藥品開發,生產變更與控制的轉化建模策略的現狀和未來期望:研討會總結報告

Current State and Future Expectations of Translational Modeling Strategies to Support Drug Product Development, Manufacturing Changes and Controls: A Workshop Summary Report.
Pepin XJ, Parrott N, Dressman J, Delvadia PR, Mitri? M, Zhang X, Babiskin AH, Kolhatkar V, Suarez-Sharp S. J Pharm Sci. May 2020. IF=3.616

5. 使用生理藥代動力學(PBPK)建模方法,建立具有臨床相關性的溶出標準

Establishment of a clinically relevant specification for dissolution testing using physiologically based pharmacokinetic (PBPK) modeling approaches.
Takafumi Kato, Hiroshi Nakagawa, Tsuyoshi Mikkaichi, Takuya Miyano, Yoshiaki Matsumoto, Shuichi Ando. Eur J Pharm Biopharm. 2020 Jun;151:45-52. IF=4.604

6. 體內外相關性IVIVC在藥物口服制劑開發中的應用:最近二十年縮影

In vitro – In vivo correlation in the development of oral drug formulation: A screenshot of the last two decades.
Marcelo Gomes Davan?o, Daniel Rossi Campos, Patrícia de Oliveira Carvalho.International Journal of Pharmaceutics. Volume 580, 30 April 2020, 119210.IF=4.845

7. 使用生物相關溶出度測試和PBPK建模了解厄貝沙坦的口服吸收

Understanding the Oral Absorption of Irbesartan Using Biorelevant Dissolution Testing and PBPK Modeling.
Kaur N, Thakur PS, Shete G, Gangwal RP, Sangamwar AT, Bansal AK. AAPS PharmSciTech. IF=2.401

8. 具有生物相關性的胃排空模擬,及胃排空對模型藥物溶出和吸收動力學的影響

The biorelevant simulation of gastric emptying and its impact on model drug dissolution and absorption kinetics.
Vrbanac H, Trontelj J, Berglez S, Petek B, Opara J, Jereb R, Krajcar D, Legen I. Eur J Pharm Biopharm. Volume 149, April 2020, Pages 113-120. IF= 4.604

9.  在Verubecestat后期臨床階段的制劑開發中支持多晶型藥物的生物豁免的應用-全球法規監管合作的當前挑戰和未來機遇

Biowaiver Applications in Support of a Polymorph During Late-Stage Clinical Development of Verubecestat—Current Challenges and Future Opportunities for Global Regulatory Alignment.
Abend A, Xiong L, Zhang X, Frankenfeld C, Kesisoglou F, Reuter K, Kotwal P. AAPS J. 2019 Dec 20;22(1):17. IF= 3.737

10.     通過PBPK吸收模型預測調釋制劑膠囊的體外-體內關系IVIVR和生物等效性

In vitro–In vivo Relationship and Bioequivalence Prediction for Modified-Release Capsules Based on a PBPK Absorption Model.
Jereb R, Opara J, Legen I, Petek B, Grabnar-Peklar D. AAPS PharmSciTech. (2020) 21: 18. IF=2.401

11. 基于生理藥代動力學PBPK模型的吡羅昔康速釋制劑BE豁免和溶出標準的可行性:深度分析

Justification of Biowaiver and Dissolution Rate Specifications for Piroxicam Immediate Release Products Based on Physiologically Based Pharmacokinetic Modeling: An In-Depth Analysis.
Xiaoting Li, Yuanhang Yang, Yu Zhang and et.al. Molecular Pharmaceutics 2019; 16 (9); 3780-3790.  IF=4.396

12. 基于PBPK模型評估甲硝唑片劑的生物等效性,并分析體外溶出對體內吸收的影響

Evaluating the bioequivalence of metronidazole tablets and analyzing the effect of in vitro dissolution on in vivo absorption based on PBPK modeling.
Shuqi Zhang, Mengna Fang, Qi Zhang, Xiaoting Li, Tianhong Zhang. Drug Dev Ind Pharm . 2019 Oct;45(10):1646-1653. IF=2.365

13.  用于口服遞送的利福平SNEDDS固體制劑:評估,概念的驗證,體內動力學,采用GastroPlus進行計算機模擬

Solidified SNEDDS for the oral delivery of rifampicin: Evaluation, proof of concept, in vivo kinetics, and in silico GastroPlusTM simulation.
Hussain A, Shakeel F, Singh SK, Alsarra IA, Faruk A, Alanazi FK, Peter Christoper GV. Int J Pharm. May 24, 2019. IF=4.845

14. 通過計算機模擬不同的溶出曲線從而預測氟康唑膠囊在血漿中的濃度,并采用群體模擬進行生物等效性研究

In Silico Prediction of Plasma Concentrations of Fluconazole Capsules with Different Dissolution Profiles and Bioequivalence Study Using Population Simulation.
Duque MD, Silva DA, Issa MG, Porta V, L?benberg R, Ferraz HG. Pharmaceutics.May 5, 2019. IF=4.421

15.  采用生理模型評價食物對克拉霉素速釋片口服吸收的影響

Evaluation of Food Effect on the Oral Absorption of Clarithromycin from Immediate Release Tablet using Physiological Modelling.
Radwan A, Jayyousi R, Shraim N, Naser Zaid A. Biopharm Drug Dispos. Mar 19, 2019. IF=1.663

16.  建立體外-體內相關的溶出和轉化建模策略-某研討會總結匯總

Dissolution and Translational Modeling Strategies Toward Establishing an In Vitro-In Vivo Link-a Workshop Summary Report.
Heimbach T, Suarez-Sharp S, Kakhi M, Holmstock N, Olivares-Morales A, Pepin X, Sj?gren E, Tsakalozou E, Seo P, Li M, Zhang X, Lin HP, Mitra A, Morris D, Patel N, Kesisoglou F. AAPS J. Feb 11, 2019. IF=3.737

17.  針對多奈哌齊和達那唑這類BCS IIc藥物速釋制劑的具有體內預測力的方法:通過GIS和USP II的雙相溶出裝置

The in vivo predictive dissolution for immediate release dosage of donepezil and danazol, BCS class IIc drugs, with the GIS and the USP II with biphasic dissolution apparatus.
Tsume Y, Igawa N, Drelich AJ, Ruan H, Amidon GE, Amidon GL. J Drug Deliv Sci Technol. Jan 30, 2019. IF=2.606

18.  通過PBPK吸收模型建立體外-體內相關-制藥工業界的觀點

PBPK Absorption Modeling: Establishing the In Vitro–In Vivo Link—Industry Perspective. 
Stillhart C, Pepin X, Tistaert C, Good D, Van Den Bergh A, Parrott N, Kesisoglou F.AAPS J. Jan 23, 2019. IF=3.737

19.   在仿制藥開發中,通過PBPK吸收模型評估BCS 2類藥物晶型和無定形兩種制劑處方的食物效應和生物等效性

PBPK Absorption Modeling of Food Effect and Bioequivalence in Fed State for Two Formulations with Crystalline and Amorphous Forms of BCS 2 Class Drug in Generic Drug Development. 
Rebeka J, Jerneja O, Igor L, Bo?tjan P, Aleksander B, Albin K. AAPS Pharm SciTech. Jan 8, 2019. IF=2.401

20.  采用基于生理學的吸收模型預測口服緩控制劑和速釋制劑的生物等效性

Physiologically based absorption modeling to predict bioequivalence of controlled release and immediate release oral products.
Mitra A, Petek B, Velagapudi R. European Journal of Pharmaceutics and Biopharmaceutics. Volume 134, January 2019, Pages 117-125. IF=4.604

21.  通過整合的PBPK模型,對比達沙替尼不同的兒科用藥制劑的生物等效性,并闡明相應的吸收機制

B
ioequivalence comparison of pediatric Dasatinib formulations and elucidation of absorption mechanisms through integrated PBPK modeling.
Vaidhyanathan S, Wang X, Crison JR, Varia S, Gao J, Saxena A, Good D. J Pharm Sci. January 2019Volume 108, Issue 1, Pages 741–749. IF=3.616

22.  受溶酶體捕獲的藥物(如右美沙芬),其制劑處方的標準制定與體外溶出不相關

The Irrelevance of in vitro Dissolution in Setting Product Specifications for Drugs like Dextromethorphan that are Subject to Lysosomal Trapping.
Bolger MB, Macwan J, Sarfraz M, Almukainzi M, L?benberg R. J Pharm Sci.Volume 108, Issue 1, January 2019, Pages 268-278. IF=3.616

23.  使用生物相關溶出方法和PBPK建模來預測口服藥物吸收

Use of Biorelevant Dissolution and PBPK Modeling to Predict Oral Drug Absorption. 
Kaur N, Narang AS, Kumar Bansal A. Eur J Pharm Biopharm. 2018 Aug; 129:222-246. IF=4.604

24.  比較體外轉換模型和體外溶出試驗獲得的卡維地洛濃度曲線
Concentration Profiles of Carvedilol: A Comparison Between In Vitro Transfer Model and Dissolution Testing.
Hamed R, Kamal A. J Pharma Innovation. 2018 July. IF=2.209

25.  基于IVIVC模型,開發Metaxalone速釋制劑臨床相關的溶出方法
Development of a Clinically Relevant Dissolution Method for Metaxalone Immediate Release Formulations Based on an IVIVC Model.
Vuleti? L, Khan MZI, ?poljari? D, Radi? M, Cetina-?i?mek B, Filipovi?-Gr?i?. J. Pharm Res. 2018 Jun 22;35(8):163. IF=3.242

26.  針對鹽酸二甲雙胍固體口服速釋制劑的體外溶出方法,并估算生物等效性豁免的結果
In Vitro Dissolution Methodology And Estimated Consequences Of Biowaiver Extension For Immediate Release Solid Oral Dosage Forms With Metformin Hydrochloride.
Ardelean M, Stoicescu SM, St?nescu AA, et,al. Farmacia, 2018, Vol. 66, 1. IF=1.607

27.  聯用胃腸道模擬器GIS和雙相溶出裝置,更好地預測BCS IIb藥物的體內釋放:以酮康唑和雷洛昔芬作為案例
The Combination of GIS and Biphasic to Better Predict In Vivo Dissolution of BCS Class IIb Drugs, Ketoconazole and Raloxifene.
Tsume Y, Igawa N, Drelich AJ, Amidon GE, Amidon GL. J Pharm Sci. 2018 Jan;107(1):307-316. IF=3.616

28.  采用多西紫杉醇載藥的PHBV-TPGS治療囊泡的工藝優化和體內的性能:一種協同的方法
Process optimization and in vivo performance of docetaxel loaded PHBV-TPGS therapeutic vesicles: A synergistic approach.
Vardhan H, Mittal P, Adena SKR, Upadhyay M, Yadav SK, Mishra B. Int J Biol Macromol. 2018 Mar;108:729-743. IF=5.162

29. 將口服藥品的數據輸入到GIS的胃腸道模型中:GIS是一種評估口服藥品性能的技術
Oral product input to the GI tract: GIS an oral product performance technology.
Amidon GL, Tsume Y. FRONT Chem Sci Eng. December 2017, Volume 11, Issue 4, pp 516–520. IF=3.552

30.  使用Gastroplus TM對呋塞米固體脂質納米顆粒進行體外-體內相關性考察,并評估其PK
In vitro–in vivo and pharmacokinetic evaluation of solid lipid nanoparticles of furosemide using Gastroplus? .
Ali H, Verma PRP, Dubey SK, Venkatesan J,et,al. RSC Adv. 2017, 7, 33314-33326.IF=3.119

31.  長效多西紫杉醇載藥的聚(3-羥基丁酸酯 - 共-3-羥基戊酸酯)納米粒子的開發:優化,藥代動力學,細胞毒性和體內評估
Development of long-circulating docetaxel loaded poly (3-hydroxybutyrate-co-3-hydroxyvalerate) nanoparticles: optimization, pharmacokinetic, cytotoxicity and in vivo assessments [J].
Vardhan H, Mittal P, Adena S K R, et al. Int J Biol Macromol, 2017 . IF=5.162

32.  非洛地平核殼型納米膠囊的研究:體外-體內相關性評價
Studies on Core-Shell Nanocapsules of Felodipine: In Vitro-In Vivo Evaluations [J].
 Geroge J K, Verma P R P, Venkatesan J, et al. AAPS Pharm SciTech, 2017: 1-18. IF=2.401 

33.  使用Gastroplus TM對卡維地洛殼聚糖小球的胃腸道滯留進行體外和體內評估

In vitro and in vivo evaluation of gastro-retentive carvedilol loaded chitosan beads using Gastroplus? [J].
Praveen R, Verma P R P, Venkatesan J, et al. International Journal of Biological Macromolecules, 2017, 102: 642-650. IF=5.162

34.  通過整合體外、建模、體內三種方法探討華法林的生物等效性

Integrating in vitro, modeling, and in vivo approaches to investigate warfarin bioequivalence. 
Zhang X, Wen H, Fan J, et al. CPT: Pharmacometrics & Systems Pharmacology,2017. CiteScore=5.2

35.   通過吸收模型和溶出試驗,探索難溶性化合物Basmisanil速釋制劑的釋放特征

Characterising Drug Release from Immediate-Release Formulations of a Poorly Soluble Compound, Basmisanil, Through Absorption Modelling and Dissolution Testing.
Stillhart C, Parrott N J, Lindenberg M, et al. AAPS J, 2017, 19(3): 827-836.IF=3.737  

36.     用于預測口服介孔二氧化硅制劑體內性能的體外溶出模型
In vitro dissolution models for the prediction of in vivo performance of an oral mesoporous silica formulation [J].
McCarthy C A, Faisal W, O'shea J P, et al. Journal of Controlled Release, 2017, 250: 86-95.  IF=7.727

37.   體外-體內相關性IVIVC:一般概念,方法,在法規監管中的應用
In vitro–in vivo correlations: general concepts, methodologies and regulatory applications [J]. 
González-García I, Mangas-Sanjuán V, Merino-Sanjuán M, et al. Drug development and industrial pharmacy, 2015, 41(12): 1935-1947.  IF=2.365

38.  開發用于描述在空腹和餐后條件下氯吡格雷片劑給藥的體外體內相關IVIVC模型

Development of in vitro in vivo correlation models for clopidogrel tablets to describe administration under fasting and fed conditions.
Savu S N, Silvestro L, Mircioiu C, et al. Farmacia, 2016, 11(16): 18. IF=1.607

39.  采用LC-ESI-MS / MS估算氯雷他定載藥的自納米乳化藥物遞送系統在大鼠血漿中的情況:藥代動力學的評估和使用GastroPlus TM的計算機模擬結果
LC-ESI-MS/MS estimation of loratadine-loaded Self-nanoemulsifying drug delivery systems in rat plasma: pharmacokinetic evaluation and computer simulations by GastroPlus?.
Verma S, Singh SK. (2016). J Pharm Biomedical Anal. Feb. 8. IF=3.209

40.  針對腸溶包衣制劑具有生物預測力的溶出方法
Toward Biopredictive Dissolution for Enteric Coated Dosage Forms.
Al-Gousous J, Amidon GL, Langguth P. (2016) Mol Pharm. May 10. IF=4.321

41.  采用PBPK吸收模型指導加波沙朵的調釋制劑處方開發,這是一種高溶解度且吸收具有胃腸道區域依賴性的化合物
Utility of PBPK Absorption Modeling to Guide Modified Release Formulation Development of Gaboxadol, a Highly Soluble Compound with Region-Dependent Absorption.
Kesisoglou F, Balakrishnan A, Manser K. (2015) J Pharm Sci. Oct 12. IF=3.616

42.  使用生理藥代動力學PBPK模型進行虛擬群體的PK模擬,從而評估拉西地平口服制劑在狗中的生物等效性

Virtual population pharmacokinetic using physiologically based pharmacokinetic model for evaluating bioequivalence of oral lacidipine formulations in dogs.
Yang B, Wu C, Ji B, Wu M, He Z, Shang L, Sun J. (2016). Asian J. Pharm. Sci. Mar.IF=3.968

43.  開發和驗證雌二醇經皮給藥系統的體內外相關性IVIVC模型

Development and validation of in vitro-in vivo correlation (IVIVC) for estradiol transdermal drug delivery systems.
Yang Y, Manda P, Pavurala N, Khan MA, Krishnaiah YS. (2015). J Control Release. May 13;210:58-66. IF=7.727

44. 生理學吸收模型在安非他命鹽型藥品的仿制藥評價中的應用

Application of Physiologically Based Absorption Modeling for Amphetamine Salts Drug Products in Generic Drug Evaluation.
Babiskin AH, Zhang X. (2015). J Pharm Sci. May 13. IF=3.616

45.  體外溶出方法和微型胃腸模擬器(mGIS),更好地預測弱堿性藥物達沙替尼的體內溶出

In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
Tsume Y, Takeuchi S, Matsui K, Amidon GE, Amidon GL. (2015). Eur J Pharm Sci.May 12;76:203-212. IF=3.616

46. 針對BCS III候選藥物的緩釋制劑開發,比較兩種IVIVC模型的效果:基于反卷積和吸收模型

Comparison of Deconvolution-Based and Absorption Modeling IVIVC for Extended Release Formulations of a BCS III Drug Development Candidate.
Kesisoglou F, Xia B, Agrawal NG. (2015). AAPS J. Aug 20. IF=3.737

47.  使用GastroPlus TM對卡維地洛載藥的納米膠囊進行體內PK模擬研究

In vivo in silico pharmacokinetic simulation studies of carvedilol-loaded nanocapsules using GastroPlus?.
George JK, Singh SK, Verma P. (2016). Ther Deliv. May;7(5):305-18. CiteScore=3.7

48.  預測不同制劑的在人和狗中的口服PK:結合生理藥代動力學PBPK模型與具有生物相關性溶出方法

Interspecies prediction of oral pharmacokinetics of different formulations from dogs to human: physiologically based pharmacokinetic modelling combined with biorelevant dissolution.
Wu C, Kou L, Ma P, Gao L, Li B, Li R, Luo C, Shentu J, Hea Z, Sun J. (2015). RSC Adv. 5: 19844. IF=3.119

49.  使用親水和疏水等級的二氧化硅Aerosil?制備氯雷他定的自微乳釋藥系統SNEDDS固體制劑,并進行PK評估,使用計算機模擬的GastroPlus?的進行體內預測

Solidified SNEDDS of loratadine: formulation using hydrophilic and hydrophobic grades of Aerosil?, pharmacokinetic evaluations and in vivo–in silico predictions using GastroPlus?. 
Verma S, Singh SK, Verma PRP. (2016) RSC Adv. 6:3099-3116. IF=3.119

50.  溶出度測試結合計算機模擬技術評估國產阿莫西林膠囊的生物等效性
Dissolution testing combined with computer simulation technology to evaluate the bioequivalence of domestic amoxicillin capsule.
Pan RX, Gao Y, Chen WL, Li YL, Hu CQ. (2014) Acta Pharmaceutica Sinica.Aug;49(8):1155-61. IF=1.736

51.  評估使用三房室體外胃腸模擬器的溶出裝置預測體內釋放的效果
Evaluation of a Three Compartment In Vitro Gastrointestinal Simulator Dissolution Apparatus to Predict In Vivo Dissolution.
Takeuchi S, Tsume Y, Amidon GE, Amidon GL. (2014). J Pharm Sci. Sept 22.IF=3.616

52.  使用吸收模型預測兩批次的艾托考昔片的生物等效性情況
Application of Absorption Modeling to Predict Bioequivalence Outcome of Two Batches of Etoricoxib Tablets.
Mitra A, Kesisoglou F, Dogterom P. (2014). AAPS Pharm SciTech. Sep 3. IF=2.401

53.  通過布洛芬固體劑型的體外溶出曲線模擬它的體內暴露情況
Simulation of the In Vivo Exposure to Ibuprofen Based on In Vitro Dissolution Profiles from Solid Dosage Forms.
Popa DE, Lupuliasa D, Stanescu AA, Barca M, Burcea Dragomiroiu GTA, Miron DS, Radulescu FS. (2014). Farmacia. 62(3):483. IF=1.607

54.  生物藥劑學分類BCS系統的亞型:用于預測體內溶出(IPD)的方法和IVIVC
The Biopharmaceutics Classification System: Subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC.
Tsume Y, Mudie DM, Langguth P, Amidon GE, Amidon GL. (2014) Eur J Pharm Sci.Jan 28. IF=3.616

55. 使用GastroPlus?建立依法韋侖片的體內-體內相關性IVIVC
In Vitro-In Vivo Correlation of Efavirenz Tablets Using GastroPlus?.
Honório TD, Pinto EC, Rocha HV, Esteves VS, Dos Santos TC, Castro HC, Rodrigues CR, de Sousa VP, Cabral LM. (2013). AAPS Pharm SciTech. Aug. 14. IF=2.401

56.  使用體內外相關性IVIVC預測幾種BCS 1類藥物緩釋骨架片的PK
Use of In Vitro-In Vivo Correlation to Predict the Pharmacokinetics of Several Products Containing a BCS Class 1 Drug in Extended Release Matrices.
Mirza T, Bykadi SA, Ellison CD, Yang Y, Davit BM, Khan MA. (2012) Pharm Res.Aug. 22. IF=3.242

57. 開發利培酮速釋片的體內-體內相關性IVIVC
Developing In Vitro–In Vivo Correlation of Risperidone Immediate Release Tablet.
Saibi Y, Sato H, and Tachiki H. (2012). AAPS Pharm SciTech. June 14. IF=2.401

58.  使用計算機模擬研究BCS III類鹽酸二甲雙胍的生物豁免方法
Biowaiver approach for biopharmaceutics classification system class 3 compound metformin hydrochloride using in silico modeling.
Crison JR, Timmins P, Keung A, Upreti VV, Boulton DW, Scheer BJ. (2012). J Pharm Sci. Feb. IF=3.616

點擊查看其他文獻


  • GastroPlus在FDA等法規部門的應用文章(2016-2020)

  • GastroPlus在PBPK、ACAT、PBBM模型應用的綜述文章(2011-2020)

  • 采用GastroPlus預測PK曲線或PK參數的應用文章(2011-2020)

  • GastroPlus在口服吸收、制劑開發等的應用文章(2011—2020)

  • GastroPlus在PK-PD結合模型的應用文章(2012—2020)

  • GastroPlus在預測特定人群PK的應用文章(2011—2020)

  • GastroPlus在預測藥物相互作用DDI的應用文章(2011 —2020)

  • GastroPlus在考察食物效應的應用文章(2013—2020)

  • GastroPlus在考特殊給藥途徑的應用文章(2012—2020)

  • GastroPlus在毒理領域的應用文章(2012年—2020年10月)

  • 評估GastroPlus預測準確性的應用(2011年—2020年 10月)

  • 中國用戶采用GastroPlus發表的應用文章(2013年—2020年10月)


  • 上一頁: GastroPlus 在口服吸收、制劑開發等的應用文章 (2011—2020 )
  • 下一頁: GastroPlus在PK-PD結合模型的應用文章 (2012—2020年10月)
logo
  • 上海市
  • 021-50263208
  • 客服微信:ipharmogo

快捷導航

  • 關于我們
  • 新聞資訊
  • 產品中心
  • 培訓中心
  • 在線申請
  • 聯系我們

關注公眾號
了解更多資訊

Copyright ? 2018-2021 上海凡默谷信息技術有限公司 All Rights Reserved.    

電話咨詢
產品中心
新聞資訊
QQ客服
久久中文字幕人妻熟女22页,久久综合中文字幕无码,亚洲欧美日韩综合俺去了,小泽玛利亚一区二区免费